阿司匹林脱敏及维持治疗在阿司匹林加重性呼吸系统疾病中的主要并发症
本研究回顾性分析2016年7月至2019年2月单中心109例AERD患者接受ESS后行阿司匹林脱敏及维持治疗,9.2%在脱敏后维持前停药,7.3%在维持治疗后停药,83.5%无并发症。仅0.92%发生临床显著消化道出血,0.92%发生过敏反应,14.7%因轻微后遗症停药。
要点
- AD联合ATAD总体耐受良好,83.5%患者无并发症。
- 临床显著消化道出血和过敏反应发生率均为0.92%。
- 14.7%患者因轻微临床后遗症停用阿司匹林。
核心结论
- AD联合ATAD在多数AERD患者中耐受良好,主要并发症发生率低。
- 临床显著消化道出血和过敏反应发生率均为0.92%。
研究设计与样本
- 回顾性病历审查,纳入2016年7月至2019年2月单中心109例接受ESS后行AD和ATAD的AERD患者。
- 采用方差分析和逻辑回归分析导致停用阿司匹林的并发症。
主要发现
- 10例(9.2%)在AD后、开始ATAD前停药,8例(7.3%)在开始ATAD后停药。
- 91例(83.5%)在整个ATAD期间无并发症。
- 停药原因包括胃炎、上消化道出血、过敏反应、持续鼻窦症状、反复鼻出血、哮喘急性发作和钱币状皮疹。
- 并发症发生率与阿司匹林剂量(ANOVA F: 0.69; p = 0.51)、性别(OR 0.56; 95%CI 0.19-1.65; p = 0.30)、年龄(OR 1.04; 95%CI 0.96-1.09; p = 0.06)或种族/民族(OR 1.12; 95%CI 0.88-1.44; p = 0.36)无显著相关。
关键数值与推荐
- 临床显著消化道出血发生率0.92%。
- 过敏反应发生率0.92%。
- 16例(14.7%)因轻微临床后遗症停用阿司匹林。
临床怎么用
- AERD患者行AD和ATAD时主要并发症风险低,可向患者说明多数人可耐受。
- 仍需监测消化道出血、过敏反应等导致停药的原因。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Treatment of aspirin-exacerbated respiratory disease (AERD) includes endoscopic sinus surgery (ESS) and aspirin desensitization (AD) with aspirin therapy after desensitization (ATAD). The objective of this study was to determine the rate of major complications associated with aspirin use that resulted in the discontinuation of aspirin therapy. METHODS: This study was a retrospective chart review of patients with AERD who underwent ESS, AD, and ATAD at a single AERD tertiary center between July 2016 and February 2019. Complications associated with aspirin that resulted in the discontinuation of aspirin therapy were analyzed via analysis of variance and logistic regression. RESULTS: In total, 109 AERD patients underwent ESS with subsequent AD. Ten patients (9.2%) discontinued therapy after AD, before starting ATAD. Eight patients (7.3%) discontinued therapy after starting ATAD. There were 91 patients (83.5%) with no complications throughout ATAD. Reasons for discontinuation included gastritis, upper gastrointestinal (GI) bleed, anaphylaxis, persistent sinonasal symptoms, recurrent epistaxis, asthma exacerbation, and a nummular rash. There was no significant correlation between complication rate and (1) aspirin doses (analysis of variance [ANOVA] F: 0.69; p = 0.51), (2) gender (odds ratio [OR] 0.56; 95% confidence interval [CI], 0.19 to 1.65; p = 0.30), (3) age (OR 1.04; 95% CI, 0.96 to 1.09; p = 0.06), or (4) race/ethnicity (OR 1.12; 95% CI, 0.88 to 1.44; p = 0.36). CONCLUSION: AD with ATAD was associated with only a 0.92% incidence of a clinically significant GI bleed, and only a 0.92% incidence of anaphylaxis. A remaining 16 patients (14.7%) discontinued aspirin therapy due to minor clinical sequelae. These findings demonstrate that the majority of AERD patients tolerate AD with ATAD without any major complications.
引用
- Sweis AM, Locke TB, Ig-Izevbekhai KI, et al. Major complications of aspirin desensitization and maintenance therapy in aspirin-exacerbated respiratory disease. Int Forum Allergy Rhinol. 2020. PMID: 32671928. doi:10.1002/alr.22643
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。